CVS Health (NYSE:CVS) Given New $100.00 Price Target at Wolfe Research

CVS Health (NYSE:CVS) had its price objective increased by equities researchers at Wolfe Research from $85.00 to $100.00 in a report released on Monday,MarketScreener reports. The brokerage presently has an “outperform” rating on the pharmacy operator’s stock. Wolfe Research’s price objective points to a potential upside of 32.98% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Jefferies Financial Group boosted their price objective on shares of CVS Health from $92.00 to $98.00 in a research note on Thursday, October 30th. Zacks Research downgraded CVS Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 8th. The Goldman Sachs Group initiated coverage on CVS Health in a research note on Tuesday, October 14th. They issued a “buy” rating and a $91.00 price target on the stock. Mizuho boosted their target price on shares of CVS Health from $76.00 to $88.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. Finally, Truist Financial reiterated a “buy” rating and issued a $95.00 price target (up previously from $92.00) on shares of CVS Health in a report on Thursday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $91.67.

CVS Health Stock Performance

Shares of CVS traded down $0.43 during midday trading on Monday, reaching $75.20. 865,811 shares of the stock were exchanged, compared to its average volume of 9,013,755. The company has a market capitalization of $95.46 billion, a price-to-earnings ratio of 197.56, a PEG ratio of 0.74 and a beta of 0.48. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. CVS Health has a twelve month low of $43.56 and a twelve month high of $85.15. The business’s 50-day moving average price is $78.75 and its 200 day moving average price is $71.35.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping the consensus estimate of $1.36 by $0.24. The company had revenue of $102.87 billion for the quarter, compared to analyst estimates of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, sell-side analysts expect that CVS Health will post 5.89 EPS for the current fiscal year.

Institutional Trading of CVS Health

A number of large investors have recently made changes to their positions in CVS. SOA Wealth Advisors LLC. raised its stake in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 131 shares during the last quarter. Alteri Wealth LLC grew its holdings in shares of CVS Health by 3.2% during the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after buying an additional 131 shares in the last quarter. Holistic Financial Partners raised its position in shares of CVS Health by 4.1% in the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock valued at $256,000 after buying an additional 133 shares during the last quarter. CYBER HORNET ETFs LLC lifted its stake in shares of CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after buying an additional 134 shares during the period. Finally, Fayez Sarofim & Co boosted its position in CVS Health by 2.1% during the third quarter. Fayez Sarofim & Co now owns 6,913 shares of the pharmacy operator’s stock worth $521,000 after acquiring an additional 140 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.